Source: Annual Congress 2001 - Pulmonary hypertension (miscellanea)
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. H. Ghofrani, H. Olschewski, F. Rose, R. T. Schermuly, N. Weissmann, R. Wiedemann, H. Tenor, C. Schudt, W. Seeger, F. Grimminger (Giessen, Konstanz, Germany). PDE 3/4 inhibition prolonges pulmonary vasodilatory response to inhaled iloprost. Eur Respir J 2001; 16: Suppl. 31, 2807

Member's Comments

No comment yet.

Related content which might interest you: Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 Protective effect of inhaled iloprost on exercise-induced bronchoconstriction Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004 Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001 The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Combination of inhaled nitric oxide and an endothelinA-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002 Inhalation of a prostacyclin analog (iloprost) does not improve exercise capacity in COPD with disproportional pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002 Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure Source: Eur Respir J 2003; 22: 342-347 Year: 2003